To further characterize the effects of the microexon inhibitor compounds in a disease-relevant context, we next performed RT-PCR assays to monitor the splicing of Srrm4-dependent microexons in the neuroendocrine small cell lung cancer (SCLC) cell line NCI-82, which aberrantly express SRRM4 and SRRM3, and in which microexons activated by these factors are included. This evidence concerns the gene SRRM4 and small cell lung carcinoma.